Chugai Pharmaceutical's Pipeline Looking Increasingly Thin — Market Talk
Chugai Pharmaceutical's mid-to late-stage pipeline is looking increasingly thin, Jefferies analysts say in a note. Roche has discontinued development of GYM329 for obesity and returned the rights to Chugai. Investors have historically afforded Chugai a premium valuation because of its track record…